No Prescription |
 |
 | ||
|
R CIN Rifadin |
|
| ||
No Prescription » Prescription Drugs 14 » R CIN Rifadin Rifampin eliminates bacteria that cause tuberculosis (TB). It is generally used with other drugs to treat tuberculosis or to eliminate Neisseria meningitidis (a bacteria) and to prevent you from giving these infections to others. However rifampin is not used to treat Neisseria meningitidis infection.Rifampin comes as a capsule to take by mouth. It usually is taken once a day. You will probably be taking it for at least 3 months and possibly for up to 2 years. Rifampin works best on an empty stomach; take it 1 hour before or at least 2 hours after a meal. If you have difficulty swallowing the capsule you may empty its contents into applesauce or jelly. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take rifampin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Buy R CIN Rifadin and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About R CIN Rifadin: Product Type: Prescription Drugs 14 R CIN ( Rifadin Rimactane Generic Rifampicin ) R CIN (Rifadin Rimactane Generic Rifampicin) Rifadin Rimactane Generic Rifampicin 150mg Caps Rifadin Rimactane Generic Rifampicin R CIN
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
